Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00656617 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 2 | 106 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2015 |
| clinicaltrials |
| NCT00528333 | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | completed | Phase 2 | 211 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00661180 | Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec(ORACLE) | completed | Phase 2 | 10 | BayerINDUSTRY | 2 | Dec 23, 2014 | clinicaltrials |
| NCT00858806 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy(INTERIM0407) | completed | Phase 2 | 78 | Università degli Studi di BresciaOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00074737 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | completed | Phase 2 | 53 | Eleos, Inc.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00742625 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00433745 | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 8, 2014 | clinicaltrials |
| NCT02182596 | DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML(MYLOFRANCE2) | completed | Phase 1 / Phase 2 | 20 | Acute Leukemia French AssociationOTHER | 1 | Jul 8, 2014 | clinicaltrials |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | completed | Phase 2 / Phase 3 | 48 | Amneal Pharmaceuticals, LLCINDUSTRY | 1 | Jun 27, 2014 | clinicaltrials |
| NCT01236144 | A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.(AML18 Pilot) | completed | Phase 1 / Phase 2 | 113 | Cardiff UniversityOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 19, 2014 | clinicaltrials |
| NCT00909168 | Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)(MYFLAI07) | completed | Phase 2 / Phase 3 | 130 | University Hospital, Udine, ItalyOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00130702 | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | May 1, 2014 | clinicaltrials |
| NCT00315705 | A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. | completed | Phase 1 / Phase 2 | 50 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00373529 | A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) | completed | Phase 2 | 116 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT02113319 | Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia(DasaCBF) | completed | Phase 2 | 27 | University Hospital, AngersOTHER_GOV | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00044889 | Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00774046 | High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | completed | Phase 2 | 32 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00016016 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT01035502 | A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia | completed | Phase 2 | 51 | Clavis PharmaINDUSTRY | 4 | Sep 27, 2013 | clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00882102 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2013 | clinicaltrials |
| NCT00684918 | Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) | completed | Phase 2 | 18 | Gemin XINDUSTRY | 2 | Aug 26, 2013 | clinicaltrials |
| NCT00360672 | Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00334074 | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | completed | Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT00460629 | Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | completed | Phase 1 / Phase 2 | 20 | University Hospital Carl Gustav CarusOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00195000 | Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | completed | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00003694 | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00049192 | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00358644 | Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 55 | Eisai Inc.INDUSTRY | 1 | May 20, 2013 | clinicaltrials |
| NCT00027872 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00797758 | Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia(MINICORD) | completed | Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00968071 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00398983 | Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | completed | Phase 2 / Phase 3 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00651781 | Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00037596 | Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia | completed | Phase 2 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Feb 13, 2013 | clinicaltrials |
| NCT00520208 | Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL(STAR-1) | completed | Phase 2 | 15 | CytRxINDUSTRY | 1 | Feb 13, 2013 | clinicaltrials |
| NCT00015834 | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005942 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006364 | Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00054431 | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00084916 | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00030394 | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00093418 | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 296 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2015source: clinicaltrials